Review
Copyright ©The Author(s) 2016.
World J Transplant. Mar 24, 2016; 6(1): 125-134
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.125
Table 1 Factors associated with lipid abnormalities after transplantation
HypercholesterolemiaHypertriglyceridemia
Genetic predispositionGenetic predisposition
AgeExcessive dietary intake of carbohydrates, cholesterol, and saturated fat
Excessive dietary intake of cholesterol and saturated fatsObesity
ObesityProteinuria
ProteinuriaRenal insufficiency
Anti-hypertensive agents, e.g., diuretics, beta-blockersCorticosteroids
CorticosteroidsMammalian target-of-rapamycin inhibitors (sirolimus)
Calcineurin-inhibitors (cyclosporine, possibly tacrolimus)
Mammalian target-of-rapamycin inhibitors (sirolimus, everolimus)
Table 2 A suggested approach to managing post-transplant dyslipidemia
Initial post-transplant periodManage acute graft-related concerns
Optimize immunosuppressive medication to graft function
2-3 mo post-transplantMeasure 8-12 h fasting lipid profile
If LDL cholesterol and/or triglyceride level above target1Dietician consult
2-3 mo post-dietary interventionMeasure 8-12 h fasting lipid profile
If LDL cholesterol and/or triglyceride level still above target1Initiate statin therapy, e.g., atorvastatin 10 mg/d or rosuvastatin 5 mg/d
Assess for potential drug interactions
Monitor creatine kinase and liver transaminase levels
2-3 mo post-statin initiationMeasure 8-12 h fasting lipid profile
If LDL cholesterol and/or triglyceride level still above target1Repeat all of the above until targets are achieved. Increase statin dose as tolerated to a maximum acceptable dose with each measurement not at target. If targets are not achieved then consider adding a supplemental agent, e.g., ezetimibe 10 mg/d
If LDL cholesterol and/or triglyceride level still above target1Consider consultation with lipid specialist
LDL and triglyceride target levels achievedAnnual monitoring of lipid levels. Consider more frequent monitoring for side effects
At all times post-transplantGauge overall cardiovascular risk